PopPK和PBPK模型指导重症儿童的梅罗胺剂量与脏干净度增加的重症儿童
Yao Liu1,2, Hua He3, Sa-Sa Zhang1
1State Key Laboratory of Natural Medicine, Jiangsu Province Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.
Pharmaceutics
|December 31, 2025
概括
标准的美罗胺剂量对于重症儿童,特别是新生儿和干净度增加的新生儿是不够的. 以年龄,功能和病原体易感性为指导的精确剂量对于有效治疗至关重要.
科学领域:
- 药理学和制药科学 药理学和制药科学
- 儿科重症监护医学 儿科重症监护医学
- 计算生物学和生物信息学
背景情况:
- 梅罗 (MEM) 是严重的儿科重症监护室 (PICU) 感染的关键抗生素.
- 在重症儿童中存在显著的药理动力学变异,影响剂量有效性.
- 目前的美罗胺剂量在易受伤害的儿科群体中缺乏充分的评估,包括新生儿和功能障碍患者.
研究的目的:
- 在重症儿科患者中评估美罗的药理动力学 (PK) 和药理动力学 (PD).
- 为了比较群体PK (PopPK) 和基于生理学的PK (PBPK) 建模方法对美洛的剂量.
- 确定最佳的美罗胺剂量策略,以实现目标达到并避免毒性.
主要方法:
- 综合PopPK和PBPK建模,使用101名儿科患者的临床数据.
- 严格的模型评估使用适合性图表和基于预测的指标.
- 蒙特卡洛模拟用于计算各种剂量方案和最小抑制度 (MIC) 的目标实现概率 (PTA).
主要成果:
- 观察到梅罗PK/PD的高个体间变异性,增强干净度 (ARC) 是一个重要因素.
- 波普克模型表现出优异的预测性能,特别是在高eGFR子组中;PBPK模型在低eGFR子组中显示出更高的精度.
- 标准的美罗胺疗法对早产新生儿 (MIC ≥4 mg/L) 和婴儿 (MIC ≥2 mg/L) 不够,需要个性化剂量.
结论:
- 无论是PBPK和PopPK模型都准确地预测了重症儿童的美罗PK,在功能水平上提供了互补的见解.
- 在ARC或MIC升高的情况下,模拟证实了标准剂量不足.
- 建议基于患者年龄,eGFR和病原体MIC的个性化,精确引导的美罗胺剂量策略,以提高疗效和安全性.
相关概念视频
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
191
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
191
01:29Drug Dosing: Infants and Children
229
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
229
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
225
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
225
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
186
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
186
01:11Renal Failure: Dose Adjustments
401
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
401